Clinical Trial Update: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II safety and toxicity study of WT1 TCR gene therapy for acute myeloid leukemia and chronic myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• WT1 TCR gene therapy (WT1-targeted TCR)

Snippet

Sponsor: Cell Medica Ltd | Conditions: Acute Myeloid Leukaemia, Chronic Myeloid Leukaemia | Phase 1, Phase 2 | Status: COMPLETED